Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

FDA-Approved Drug Could Be Repurposed to Relieve Osteoarthritis Pain And Protect Cartilage : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-10-13

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One claim goes further than the study. 5 other points were not covered by the paper.

  • 2 supported
  • 1 overstated
  • 5 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

One claim overstates the study. Two of eight check out. Five claims the study doesn't address.

  • 2 supported
  • 1 overstated
  • 5 not covered
Open claim evidence
3
Source paper

Source layer

The 3 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8OverstatedA team from Yale School of Medicine found that the epilepsy drug lacosamide could also be effective in osteoarthritis, easing pain and reversing some joint damage.View evidenceHide evidence

As statedcould also be effective

Why this verdict

The abstract-level profile supports preclinical lacosamide effects on OA-relevant biology: anabolic/anti-catabolic effects in primary human OA chondrocytes, reduced cartilage degeneration, and reduced pain behaviors in murine DMM OA. But the lead wording that it could be effective in OA while “reversing” joint damage goes beyond the abstract evidence, which reports protection/reduced degeneration and anabolic markers rather than demonstrated reversal of established joint damage or clinical effectiveness in patients.

1

Study evidence

Lacosamide (LCM) more potently suppressed IL-1β-induced catabolic responses and promoted anabolic responses in primary human OA chondrocytes than carbamazepine or oxcarbazepine.

“Sodium channel inhibitors (carbamazepine, oxcarbazepine, and LCM) were evaluated in primary human OA chondrocytes”
2

Study evidence

Systemic lacosamide reduced cartilage degeneration in the murine DMM osteoarthritis model.

“... a murine DMM model with systemic or intra-articular administration”
Claim 2 of 8Not coveredThe researchers identified a 'sweet spot' or optimal dose range where the drug was most beneficial, with little drug needed.View evidenceHide evidence

As statedan optimal range

Why this verdict

The profile supports dose-related ideas in a limited way: lacosamide showed efficacy at lower concentrations than comparator sodium-channel inhibitors in chondrocytes, and intra-articular dosing worked at one-tenth the systemic dose in mice. However, the abstract-level profile does not describe a “sweet spot,” an optimal therapeutic range, or an overcorrection threshold, so that specific framing cannot be verified at this evidence depth.

1

Study evidence

Lacosamide (LCM) more potently suppressed IL-1β-induced catabolic responses and promoted anabolic responses in primary human OA chondrocytes than carbamazepine or oxcarbazepine.

“Sodium channel inhibitors (carbamazepine, oxcarbazepine, and LCM) were evaluated in primary human OA chondrocytes”
2

Study evidence

Intra-articular lacosamide conferred superior protection against cartilage degeneration and superior analgesia in the murine DMM model when delivered at one-tenth the systemic dose.

“... a murine DMM model with systemic or intra-articular administration”
Claim 3 of 8Not coveredIn mice, injecting the drug directly into the affected joint worked better than giving it orally, even at lower doses, but the effect did not last long without repeat dosing.View evidenceHide evidence

As statedworked better ... even at lower doses

Why this verdict

The abstract supports that intra-articular lacosamide produced superior joint protection and analgesia at one-tenth the systemic dose in murine DMM OA. However, the profile says “systemic,” not specifically oral dosing, and the abstract-level profile does not verify the statement that the effect did not last long without repeat dosing. The main route-comparison is supported, but material details are not verifiable from the abstract profile.

1

Study evidence

Systemic lacosamide reduced cartilage degeneration in the murine DMM osteoarthritis model.

“... a murine DMM model with systemic or intra-articular administration”
2

Study evidence

Intra-articular lacosamide conferred superior protection against cartilage degeneration and superior analgesia in the murine DMM model when delivered at one-tenth the systemic dose.

“... a murine DMM model with systemic or intra-articular administration”
Claim 4 of 8Not coveredPacking lacosamide into a hydrogel was used to keep it in the joint longer, with the article saying it could stay active for a month or longer.View evidenceHide evidence

As stateda month or longer

Why this verdict

The profile supports that a collagen II-based thermoresponsive hydrogel prolonged intra-articular retention of lacosamide and enhanced durability of therapeutic effects in mice. But the abstract-level profile does not provide a duration such as “a month or longer,” nor does it quantify how long the drug stayed active. The specific duration claim cannot be verified at this depth.

1

Study evidence

A collagen II-based thermoresponsive hydrogel prolonged intra-articular retention of lacosamide and enhanced the durability of its therapeutic effects in a murine OA model.

“A collagen II-based thermoresponsive hydrogel was developed for sustained intra-articular delivery”
Claim 5 of 8Not coveredThe article says the findings still need to be tested in actual osteoarthritis patients, but the approved-drug status of lacosamide could speed clinical testing.View evidenceHide evidence

Why this verdict

The need for testing in actual OA patients is consistent with the profile’s translational limitations: evidence is preclinical, including murine DMM models and human cell/explant systems. However, the profile does not verify that lacosamide’s approved-drug status would speed clinical testing, nor does it provide regulatory or clinical-development evidence for that claim.

1

Study evidence

Systemic lacosamide reduced cartilage degeneration in the murine DMM osteoarthritis model.

“... a murine DMM model with systemic or intra-articular administration”
2

Study evidence

Intra-articular lacosamide conferred superior protection against cartilage degeneration and superior analgesia in the murine DMM model when delivered at one-tenth the systemic dose.

“... a murine DMM model with systemic or intra-articular administration”
Claim 6 of 8Not coveredThe story notes that the research was published in Bioactive Materials and points to prior Yale work on Nav1.7 as well as earlier research suggesting lacosamide can be an effective painkiller.View evidenceHide evidence

Why this verdict

The supplied paper profile does not include bibliographic metadata verifying publication in Bioactive Materials, nor does it profile prior Yale work or earlier lacosamide painkiller studies. Those may be true externally, but they are not verifiable from the supplied abstract-level paper profile.

Claim 7 of 8SupportedThe published results, in mouse models and human cartilage cells in the lab, showed lacosamide could encourage cartilage repair, slow cartilage deterioration, and reduce pain.View evidenceHide evidence

As statedencouraging cartilage repair, slowing deterioration, and reducing pain

Why this verdict

This claim is framed as results from mouse models and human cartilage cells, which matches the profile. The abstract reports that lacosamide promoted anabolic responses and suppressed catabolic responses in primary human OA chondrocytes, reduced cartilage degeneration in a murine DMM model, and reduced pain behaviors by von Frey/open-field testing. The abstract does not provide magnitudes, but the qualitative claim is supported.

1

Study evidence

Lacosamide (LCM) more potently suppressed IL-1β-induced catabolic responses and promoted anabolic responses in primary human OA chondrocytes than carbamazepine or oxcarbazepine.

“Sodium channel inhibitors (carbamazepine, oxcarbazepine, and LCM) were evaluated in primary human OA chondrocytes”
2

Study evidence

Systemic lacosamide reduced cartilage degeneration in the murine DMM osteoarthritis model.

“... a murine DMM model with systemic or intra-articular administration”
Claim 8 of 8SupportedThe team says lacosamide works by dialing down Nav1.7, a sodium channel implicated in both pain signaling and cartilage breakdown, making it a dual-acting target.View evidenceHide evidence

Why this verdict

The profile states that Nav1.7 is implicated in both chondrocyte metabolism and pain, motivating lacosamide as a dual-acting sodium-channel/Nav1.7-targeting approach. The abstract also reports mechanistic findings involving increased HSP70 and midkine secretion. Thus the broad Nav1.7 dual-target framing is supported, though the full causal chain and exact mechanism are not detailed in the abstract.

1

Study evidence

Lacosamide (LCM) more potently suppressed IL-1β-induced catabolic responses and promoted anabolic responses in primary human OA chondrocytes than carbamazepine or oxcarbazepine.

“Sodium channel inhibitors (carbamazepine, oxcarbazepine, and LCM) were evaluated in primary human OA chondrocytes”
2

Study evidence

Systemic lacosamide reduced cartilage degeneration in the murine DMM osteoarthritis model.

“... a murine DMM model with systemic or intra-articular administration”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Human cartilage explant experiments were included as an ex vivo tissue-level platform, but the abstract profile does not provide explant-specific results or effect sizes.

    The story mentions human cartilage cells in the lab but does not distinguish the ex vivo cartilage explant work. Because the abstract itself lacks explant-specific findings, this omission is not as central as the animal and chondrocyte results, but it is a paper element not clearly reflected.

    From ex_vivo_human_cartilage_explant

5 things the story did carry across
  • Primary human OA chondrocyte experiments found lacosamide more potently suppressed IL-1β-induced catabolic responses and promoted anabolic responses than carbamazepine or oxcarbazepine, with effects at lower concentrations.
  • Murine DMM OA studies found systemic lacosamide reduced cartilage degeneration and pain behaviors and outperformed carbamazepine at equivalent systemic doses.
  • Intra-articular lacosamide provided superior cartilage protection and analgesia at one-tenth the systemic dose in the murine DMM model.
  • A collagen II-based thermoresponsive hydrogel was developed for sustained intra-articular lacosamide delivery, prolonging joint retention and enhancing durability of effects in mice.
  • Major translational limitation: evidence comes from preclinical systems, including primary human cells/explants and murine DMM OA models, not osteoarthritis patients.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

6

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalTest LCM efficacy on cartilage degeneration and pain behaviors in a murine DMM osteoarthritis model, comparing systemic vs intra-articular delivery and benchmarking against carbamazepine/oxcarbazepine.in vivo animal DMM model; intra-articular vs systemic dosing comparisonExpand

In plain English

In a murine DMM osteoarthritis model, intra-articular administration of lacosamide (LCM) achieved superior protection against cartilage degeneration and analgesia at one-tenth the systemic dose; systemic LCM also reduced cartilage degeneration and pain and outperformed carbamazepine at equivalent doses (abstract).

Key findings

  • Intra-articular lacosamide conferred superior protection against cartilage degeneration and superior analgesia in the murine DMM model when delivered at one-tenth the systemic dose.
  • Systemic lacosamide reduced cartilage degeneration and pain in the DMM model and outperformed carbamazepine at equivalent doses.
“... a murine DMM model with systemic or intra-articular administration”
What this piece can’t prove
  • Summary based solely on the abstract; no access to full methods, raw data, sample sizes, or statistical analyses.
  • Abstract does not specify exact doses, dosing schedules, number of animals, randomization, or blinding.

2 further details could not be confirmed from the summary.

2in vitroEvaluate sodium channel inhibitors—especially lacosamide (LCM)—as disease-modifying candidates in osteoarthritis by testing effects on human OA chondrocyte catabolism/anabolism and cartilage explant responses.Primary human OA chondrocyte culture; IL-1β stimulation; comparative small-molecule dosing (LCM, carbamazepine, oxcarbazepine)Expand

In plain English

In primary human osteoarthritis (OA) chondrocytes stimulated with IL-1β, lacosamide (LCM) more potently suppressed catabolic responses and promoted anabolic responses than carbamazepine or oxcarbazepine, with efficacy observed at lower concentrations. Readouts included gene expression and protein measurements (ELISA); LCM treatment was also associated with increased secretion of HSP70 and midkine, proposed as mediators of its anabolic/anti-catabolic effects.

Key findings

  • Lacosamide (LCM) more potently suppressed IL-1β-induced catabolic responses and promoted anabolic responses in primary human OA chondrocytes than carbamazepine or oxcarbazepine.
  • LCM demonstrated greater efficacy at lower concentrations compared with carbamazepine and oxcarbazepine in the in vitro IL-1β-stimulated chondrocyte model.
“Sodium channel inhibitors (carbamazepine, oxcarbazepine, and LCM) were evaluated in primary human OA chondrocytes”
What this piece can’t prove

2 further details could not be confirmed from the summary.

3ex vivo humanEvaluate sodium channel inhibitors—especially lacosamide (LCM)—as disease-modifying candidates in osteoarthritis by testing effects on human OA chondrocyte catabolism/anabolism and cartilage explant responses.ex vivo human cartilage explantExpand

In plain English

The study reports use of ex vivo human cartilage explants to evaluate sodium channel inhibitors (carbamazepine, oxcarbazepine, and lacosamide) with tissue-level readouts; the abstract lists histology, immunohistochemistry, ELISA, and gene expression as outcomes but does not present explant-specific results or effect sizes.

Key findings

  • The abstract indicates cartilage explants were evaluated with the listed sodium channel inhibitors and assessed by histology/IHC, ELISA, and gene expression, but does not report explant-specific experimental results or quantitative effects in the abstract.
“Sodium channel inhibitors ... were evaluated in ... cartilage explants”
What this piece can’t prove
  • Abstract does not provide explant-specific results, sample sizes, treatment concentrations, treatment durations, or statistical analyses.
  • Cannot determine which specific histologic, immunohistochemical, ELISA, or gene expression endpoints were measured in explants based on the abstract.

1 further detail could not be confirmed from the summary.

4in vivo animalTest LCM efficacy on cartilage degeneration and pain behaviors in a murine DMM osteoarthritis model, comparing systemic vs intra-articular delivery and benchmarking against carbamazepine/oxcarbazepine.In vivo murine DMM efficacy study comparing systemic vs intra-articular lacosamide and benchmarking against carbamazepineExpand

In plain English

In a murine destabilization of the medial meniscus (DMM) osteoarthritis model, systemic administration of lacosamide (LCM) reduced cartilage degeneration and alleviated pain behaviors; LCM outperformed carbamazepine when given at equivalent systemic doses. Intra-articular delivery produced superior joint protection and analgesia at one-tenth the systemic dose. Outcomes were assessed by behavioral testing (von Frey mechanical sensitivity, open-field) and joint histology/immunohistochemistry; mechanistic data indicate increased HSP70 and midkine secretion associated with anabolic and anti-catabolic responses.

Key findings

  • Systemic lacosamide reduced cartilage degeneration in the murine DMM osteoarthritis model.
  • Systemic lacosamide reduced pain behaviors in the murine DMM model as measured by von Frey and open-field testing.
“... a murine DMM model with systemic or intra-articular administration”
What this piece can’t prove
  • Abstract provides no numeric effect sizes, sample sizes, confidence intervals, or p-values for in vivo outcomes.
  • Species/model limitation: findings are from a murine surgical OA model and may not directly translate to humans.

2 further details could not be confirmed from the summary.

5in vitroElucidate a mechanistic pathway whereby LCM increases HSP70 and midkine secretion to drive anabolic and anti-catabolic responses.in vitroExpand

In plain English

The abstract reports that lacosamide (LCM) increases secretion of HSP70 and midkine, which is proposed to mediate anabolic and anti-catabolic responses in cartilage-related assays; these mechanistic outcomes were assessed using protein secretion measurements and gene expression analyses (methods not fully detailed in the abstract).

Key findings

  • Lacosamide increased secretion of HSP70 and midkine, which the authors state drives anabolic and anti-catabolic responses.
“Mechanistically, LCM increased HSP70 and midkine secretion to drive anabolic and anti-catabolic responses.”
What this piece can’t prove
  • Unclear whether mechanistic observations derive from in vitro, ex vivo, or in vivo experiments and whether causal perturbation experiments were performed.

2 further details could not be confirmed from the summary.

6in vivo animalDevelop and evaluate a collagen II-based thermoresponsive hydrogel for sustained intra-articular delivery of LCM, assessing joint retention and durability of therapeutic effects.in vivo animalExpand

In plain English

The authors developed a collagen II-based thermoresponsive hydrogel to enable sustained intra-articular delivery of lacosamide (LCM) and reported that hydrogel-mediated delivery prolonged joint retention of LCM and enhanced the durability of therapeutic effects in a murine osteoarthritis model, with outcomes assessed by histology, immunohistochemistry (IHC), ELISA, and gene expression analyses.

Key findings

  • A collagen II-based thermoresponsive hydrogel prolonged intra-articular retention of lacosamide and enhanced the durability of its therapeutic effects in a murine OA model.
“A collagen II-based thermoresponsive hydrogel was developed for sustained intra-articular delivery”
What this piece can’t prove
  • The specific methods used to measure 'joint retention' and the temporal duration of retention/durability are unspecified.

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 17 candidate papers

Candidate

Clinical pain severity and experimental pain sensitivity in osteoarthritis

Osteoarthritis and Cartilage · 2012 · Crossref

Source (opens in a new tab)

And 11 more candidates considered.